NEORX CORPORATION CHANGE OF CONTROL AGREEMENT (VP)Change of Control Agreement • March 29th, 2002 • Neorx Corp • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this “Agreement”), dated as of , 20 , is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the “Company”), and (the “Executive”).
CLINICAL SUPPLY AGREEMENTClinical Supply Agreement • March 29th, 2002 • Neorx Corp • In vitro & in vivo diagnostic substances
This agreement (the “Agreement”) is entered into effective as of December 1, 2001 by and between The Curators of The University of Missouri, a public corporation of the State of Missouri, contracting on behalf of its Research Reactor Center, University of Missouri-Columbia (hereafter “University”), and NeoRx Corporation, a Washington corporation (“NeoRx”). University and NeoRx may hereafter from time to time be referred to collectively as the “Parties” and individually as a “Party.”
NEORX CORPORATION KEY EXECUTIVE SEVERANCE AGREEMENT (VP)Executive Severance Agreement • March 29th, 2002 • Neorx Corp • In vitro & in vivo diagnostic substances
This Key Executive Severance Agreement (VP) (this “Agreement”), dated as of , 20 , is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 10, the “Company”), and (the “Executive”).
September 13, 2001Change of Control Agreement • March 29th, 2002 • Neorx Corp • In vitro & in vivo diagnostic substances
Upon your signing below the following will constitute the agreement of you and NeoRx Corporation (“NeoRx”) regarding your employment.
Amendment Three to Letter AgreementLetter Agreement • March 29th, 2002 • Neorx Corp • In vitro & in vivo diagnostic substances
WHEREAS, this Amendment Three to Letter Agreement shall be effective January 1, 2002, and amends that certain Letter Agreement made between NeoRx Corporation (hereinafter referred to as NeoRx), 410 West Harrison Street, Seattle, WA 98119, and Bay City Capital BD LLC (hereinafter referred to as Bay City), 750 Battery, Suite 600, San Francisco, CA 94111, said original Letter Agreement being dated August 16, 2000 (and agreed to and accepted by NeoRx Corporation on August 31, 2000) and as amended, and
OFFICE LEASEOffice Lease • March 29th, 2002 • Neorx Corp • In vitro & in vivo diagnostic substances • Washington
THIS LEASE, made the 15th day of February, 2002, by and between SELIG REAL ESTATE HOLDINGS SIX, a Washington general partnership, whose address is 1000 Second Avenue, Suite 1800, Seattle, Washington, 98104-1046, hereinafter referred to as “Lessor” and NEORX CORPORATION INC., a Washington corporation, whose address is 410 West Harrison Street, Seattle, Washington, 98119, hereinafter referred to as “Lessee”.
